Addex Therapeutics Ltd (ADXN)

Every figure this model derived for ADXN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,273 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2024-12-31
cash 2,307,988 CashAndCashEquivalents 2025-06-30
current assets 2,657,580 CurrentAssets 2025-06-30
current liabilities 1,150,446 CurrentLiabilities 2025-06-30
equity 7,212,726 Equity 2025-06-30
interest expense 1,609 InterestExpense 2024-12-31
ocf -5,373,554 CashFlowsFromUsedInOperatingActivities 2024-12-31
revenue 404,102 RevenueFromContractsWithCustomers 2024-12-31
sbc 17,544 ExpenseFromSharebasedPaymentTransactionsWithEmployees 2024-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up ADXN on one particular measure came for.

RatioValue
cash operating margin-613.1
current ratio2.31
current ratio reported2.31
dilution pct31.96
ev owner earnings-85.44
ev sales1140.16
fcf margin-1330.07
interest cover-1712.39
operating margin-681.82
owner earnings margin-1334.41
revenue growth-74.95
revenue growth per share-81.01
roic-44.0
rule of 40-756.76
sbc pct revenue4.34

What to be careful about

What this model itself distrusts about ADXN's figures. Written by the derivation as it ran, not added afterwards.